Telefon ve e-posta Desteği
Sıkça Sorulan Sorular
Yazarlar İçin Teknik Bilgiler
İletişim Bilgileri
Ana Sayfaya Dönüş
 

Kongre Takvimi
Buradaki bilgiler JournalAgent™ online dergicilik sisteminden alınmaktadır.

The Anatolian Journal of Cardiology

[Anatol J Cardiol]
Anatol J Cardiol. 2016; 16(1): 16-22 | DOI: 10.5152/akd.2015.5708  

Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation

Lütfü Aşkın1, Şule Karakelleoğlu1, Hüsnü Değirmenci1, Selami Demirelli2, Ziya Şimşek1, Muhammed Hakan Taş1, Selim Topçu1, Zakir Lazoğlu1
1Department Of Cardiology, Faculty Of Medicine, Atatürk University; Erzurum-turkey
2Department Of Cardiology, Erzurum Education And Research Hospital; Erzurum-turkey

Objective: Serum gamma-glutamyltransferase (GGT) and uric acid levels measured in patients with acute coronary syndrome without ST segment elevation (NSTEMI) are important in diagnosis and in predicting the prognosis of the disease. There is a limited number of clinical studies investigating the effects of beta-blockers on GGT and uric acid levels in these patients. In our study, we aimed to investigate the effects of beta-blocker therapy on GGT and uric acid levels.
Methods: We conducted a randomized, prospective clinical study. Hundred patients with NSTEMI were included in this study, and they were divided into two groups. Fifty patients were administered metoprolol succinate treatment (1 x 50 mg), whereas the remaining 50 patients were administered carvedilol treatment (2 x 12.5 mg). Thereafter, all of the patients underwent coronary angiography. Blood samples were taken at the time of admission, at the 1st month, and 3rd month to detect GGT and uric acid levels.
Results: There was no statistically significant difference among the metoprolol or carvedilol groups in terms of the GGT levels measured at the baseline, 1st month, and 3rd month (p=0.904 and p=0.573, respectively). In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).
Conclusion: We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI.

Keywords: acute coronary syndrome, carvedilol, gamma-glutamyltransferase, metoprolol, uric acid


Lütfü Aşkın, Şule Karakelleoğlu, Hüsnü Değirmenci, Selami Demirelli, Ziya Şimşek, Muhammed Hakan Taş, Selim Topçu, Zakir Lazoğlu. Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation. Anatol J Cardiol. 2016; 16(1): 16-22

Sorumlu Yazar: Lütfü Aşkın, Türkiye


ARAÇLAR
Tam Metin PDF
Yazdır
Alıntıyı İndir
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
E-Postala
Paylaş
Yazara e-posta gönder

Benzer makaleler
PubMed
Google Scholar




 

 
 

Online Kongre Hizmetleri
Kongre Web Sitesi
Bildiri Özeti Toplama ve Değerlendirme
Online Kayıt ve Konaklama
Elektronik Poster (e-poster)
Video Podcast, WebCast
Bilimsel Program Düzenleyici
Bildiri Özeti ve Tam Metin CD'leri
 

Online Kurumsal Hizmetler
Dernekler İçin Web Siteleri
Hakemli Dergiler İçin Online Makale Toplama
   ve Değerlendirme

Uluslararası Dizin Danışmanlığı
PubMed®, LinkOut® Hizmetleri
Online Çalışma Grupları
 

Referans
Çalıştığımız Online Hakemli Dergiler
Destek Verdiğimiz Kongreler
Yazarlar İçin Teknik Bilgiler

İletişim
Bize Ulaşın
LookUs

 
 
1999 - 2019 © LookUs Scientific

Bu sitede sözü edilen uygulamalara ait teknoloji, uygulama metodu, ekran görünüşleri; ticari marka, ticari görünüm, kanun dışı rekabet ve başka kanunlarca; yerel ve uluslararası copyright düzenlemeleri ile korunmuştur. Site üzerindeki herhangi bir metin ve imaj LookUs Bilişim Hizmetleri Ltd.'nin açık ve net izni olmadan kopyalanamaz veya dağıtılamaz.
Metinler ve şekiller içinde geçen gerçek şirket ve ürün adları, ilgili firmaların ticari markaları olabilir.